Cardiologyí features high-quality papers from all over the world to keep its readers regularly informed of current strategies in the prevention, diagnosis and treatment of heart disease. These papers not only describe but offer critical appraisals of new developments in non-invasive, invasive, diagnostic and therapeutic methods. The importance of experimental work is also acknowledged through reports covering the function and metabolism of the heart and the morphology and physiology of cardiovascular disease. Special sections in a variety of subspecialty areas reinforce the journalís value as a complete record of recent progress for all cardiologists, internists, cardiac surgeons and clinical physiologists.''Cardiology'' publishes original reports in research and observations pertaining to cardiovascular physiology, epidemiology, pharmacology, disease and therapy.Only original papers written in English are considered. The articles should be readily comprehensible to a reader who is fluent in English. Therefore, all manuscripts originating from non-English-speaking authors must be edited prior to submission to assure that standard English grammar and usage are observed. This may require help from a colleague or other editorial assistant. It must be evident from the covering letter that this has been done. Submissions that are not edited in this way will not be considered for publication until such editing has been achieved.Manuscripts should be submitted onlineOnline Manuscript Submission Main SectionsOriginal ResearchOriginal Research – Clinical Trial DesignSubmissions will be accepted reporting the study design protocols of planned clinical trials that have been appropriately registered with regulatory authorities. These submissions will be limited to 4500 words and 35 references.ReviewTurning Basic Research into Clinical SuccessOne or two focused review articles are published in each issue, and should offer an overview of existing concepts and literature in a format assimilable to the largely clinical cardiologist readership, i.e. a readership base with limited sophistication as to methods and terminology associated with cell and molecular biology. Most manuscripts are submitted upon invitation. Authors planning to submit an unsolicited paper are requested to contact the Editorial Office with an outline of the intended contribution. All submissions are subject to peer review. These articles are available also to nonsubscribers in free access on the journal''s website. Submissions should comprise no more than 4,500 words and 50 references. They should have an abstract of approximately 200 words and about 5 key words should be provided.Letter to the EditorLetters to the Editor (max. 1,500 words, including references) are encouraged if they directly concern articles previously published in this journal and issues raised by those articles. The Editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal.Novel Insights from Clinical Experience (formerly Case Reports)Contributions to this section are expected to provide novel insight into a clinical problem. Submissions can be based on a single case or a number of similar cases. While a case report can describe an entirely novel clinical condition, we recognise that it is unlikely that most case reports will provide such information. In the more common setting of a description of a well-recognized condition, the most important aspect of the presentation, on which editorial judgments will be based, is the description of the new perspective(s) on the phenotype, pathophysiology, clinical presentation, evaluation strategy and/or management that can be drawn from the case findings.Highlighted boxes containing one or two bullet points on ''Established facts''and ''Novel insights'' are required and should be placed on the first page of the report. These should be selected so as to reinforce the novelty of the clinical observation.

《心臟病學》以來自世界各地的高質量論文為特色，定期向讀者介紹當前預防、診斷和治療心臟病的策略。這些論文不僅描述了非侵入性、侵入性、診斷性和治療性方法的新發展，而且提供了批判性的評價。通過報道心臟的功能和代謝以及心血管疾病的形態學和生理學，也認識到實驗工作的重要性。在各種子專業領域的特殊部分加強了期刊的價值，作為所有心臟病學家、內科醫生、心臟外科醫生和臨床生理學家的最新進展的完整記錄。《心臟病學》發表有關心血管生理學、流行病學、藥理學、疾病和治療的研究和觀察的原始報告。只有英文原版論文才會被考慮。這些文章應該易于英語流利的讀者理解。因此，所有來自非英語作者的手稿必須在提交前進行編輯，以確保遵守標準的英語語法和用法。這可能需要同事或其他編輯助理的幫助。從求職信中可以明顯看出，這一點已經做到了。沒有以這種方式編輯的投稿，在編輯完成之前不會被考慮出版。稿件應在網上提交在線提交手稿 主要部分原始研究原始研究-臨床試驗設計提交的報告將被接受，報告已在監管部門適當注冊的計劃臨床試驗的研究設計方案。這些意見書將被限制在4500字和35參考文獻。審查將基礎研究轉化為臨床成功每期發表一至兩篇重點綜述文章，并應以一種主要為臨床心臟病學家讀者所能接受的格式，對現有的概念和文獻進行概述，即讀者基礎對與細胞和分子生物學相關的方法和術語了解有限。大多數稿件是應邀提交的。計劃主動投稿的作者請與編輯部聯系，提供投稿提綱。所有參賽作品均須經同行評審。非訂閱者也可以免費訪問《華爾街日報》網站上的這些文章。提交的論文不應超過4500字和50篇參考文獻。他們應該有一個大約200字的摘要和大約5個關鍵字應該提供。致編輯的信給編輯的信(麥克斯)如果直接涉及到本期刊以前發表的文章以及這些文章所提出的問題，則鼓勵使用1500字(包括參考文獻)。編輯保留在發表前向有關文章的作者提交此類信件副本的權利，以便允許他們在同一期雜志上作出答復。臨床經驗的新見解(以前的病例報告)對這部分的貢獻有望為臨床問題提供新的見解。提交可以基于單個案例，也可以基于多個類似案例。雖然病例報告可以描述一種全新的臨床情況，但我們認識到，大多數病例報告不太可能提供此類信息。設置更為普遍的公認條件的描述,最重要的方面表示,將編輯判斷依據,是新視角的描述(s)表型,病理生理學、臨床表現,評價策略和/或管理可以從這樣的發現。在報告的第一頁，需要用高亮顯示的方框，其中包含關于“既定事實”和“新穎見解”的一兩個要點。這些應加以選擇，以加強臨床觀察的新穎性。